secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001655759-24-000056
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas Q1 cash $1.17B, licenses ARV-766 to Novartis for $150M upfront
----------------------------------------------------------------------

- Q1 2024 revenue $25.3M, down from $32.5M YoY; R&D expenses $84.3M vs $95.3M YoY.
- Cash, equivalents and marketable securities $1,174.8M as of March 31, down $91.7M from year-end.
- Licensed ARV-766 to Novartis for $150M upfront, up to $1.01B in milestones plus royalties.
- Top-line data for vepdegestrant Phase 3 VERITAC-2 trial on track for 2H 2024.
- Phase 1 trial initiated for ARV-102 (LRRK2 degrader) in neurodegenerative diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000056/0001655759-24-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000056/arvn-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001655759-24-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer